Citations

Clear

95 citation(s) found for "Boeve, Brad".

Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration
Olney, Nicholas , Ong, Elise, Goh, Sheng‐Yang M., Bajorek, Lynn, Dever, Reilly, Staffaroni, Adam M. , Bock, Meredith , Chiang, Kevin, Ljubenkov, Peter A. , Kornak, John , Heuer, Hilary W. , Rascovsky, Katya, Wolf, Amelia, Bove, Jessica, Bordelon, Yvette , Brannelly, Patrick , Brushaber, Danielle , Caso, Christine, Coppola, Giovanni , Dickinson, Susan, Domoto‐Reilly, Kimiko , Faber, Kelly, Ferrall, Jessica, Fields, Julie A. , Fishman, Ann, Foroud, Tatiana M., Forsberg, Leah K. , Gearhart, Debra, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff‐Radford, Neill R. , Grant, Ian , Haley, Dana , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Karydas, Anna M., Kaufer, Daniel , Kramer, Joel H. , Kraft, Ruth, Kremers, Walter K. , Kukull, Walter A. , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott M., McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Onyike, Chiadi U. , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Len, Potter, Madeleine, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Roberson, Erik D. , Rogalskı, Emily , Sengdy, Pheth, Shaw, Leslie M. , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Boxer, Adam L. , Rosen, Howard J. , consortia, on behalf of the ARTFL and LEFFTDS, Gearhart, Debra J, Boeve, Brad F, Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Cobigo, Yann , Wang, Ping , Appleby, Brian S. , Dickerson, Bradford Clark , Fong, Jamie , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Jones, David T. , Kerwin, Diana , Knopman, David S. , Lapid, Maria I. , Litvan, Irene , Potter, Madeleine, Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F. , consortia, on behalf of the ARTFL and LEFFTDS

Mayo Clinic

Alzheimer's & Dementia | November 26, 2019 | Volume: 16 | Issue: 1 | Pages: 49-59

10.1016/j.jalz.2019.08.196 | PMID 31784375 Get It

AbstractIntroductionThe Advancing Research and Treatment in Frontotemporal Lobar Degeneration and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects longitudinal studies were designed to describe the natural history of familial‐frontotemporal lobar degeneration due to autosomal dominant mutations.MethodsWe examined cognitive performance, behavioral ratings, and brain volumes from the first time point in 320 MAPT, GRN, and C9orf72 family members, including 102 non–mutation carriers, 103 asymptomatic carriers, 43 mildly/questionably symptomatic carriers, and 72 carriers with dementia.ResultsAsymptomatic carriers showed similar scores on all clinical measures compared with noncarriers but reduced frontal and temporal volumes. Those with mild/questionable impairment showed decreased verbal recall, fluency, and Trail Making Test performance and impaired mood and self‐monitoring. Dementia was associated with impairment in all measures. All MAPT carriers with dementia showed temporal atrophy, but otherwise, there was no single cognitive test or brain region that was abnormal in all subjects.DiscussionImaging changes appear to precede clinical changes in familial‐frontotemporal lobar degeneration, but specific early clinical and imaging changes vary across individuals.
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
Jack, Clifford R. , Wiste, Heather J. , Botha, Hugo , Weigand, Stephen D. , Therneau, Terry M. , Graff‐Radford, Jonathan , Ferman, Tanis J. , Boeve, Bradley F. , Kantarci, Kejal , Lowe, Val J. , Vemuri, Prashanthi , Fields, Julie A. , Senjem, Matthew L. , Gunter, Jeffrey L. , Petersen, Ronald C. , Jack, Clifford R , Boeve, Brad , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal , Botha, Hugo , Ferman, Tanis J , Knopman, David S. , Jones, David T. , Mielke, Michelle M. , Machulda, Mary M. , Schwarz, Christopher G.

Mayo Clinic

Brain | August 28, 2019 | Volume: 142 | Issue: 10 | Pages: 3230-3242

10.1093/brain/awz268 | PMID 31501889 Get It

See Gordon and Tijms (doi:10.1093/brain/awz278) for a scientific commentary on this article. Jack et al. examine relationships between the bivariate distribution of β-amyloid and tau on PET and established neurocognitive clinical syndromes. Amyloidosis appears to be required for high levels of 3R/4R tau deposition. Whereas abnormal amyloid PET is compatible with normal cognition, highly abnormal tau PET is not.
Neuroprotection in idiopathic REM sleep behavior disorder: a role for exercise?
McCarter, Stuart J. , Boeve, Bradley F. , Graff‐Radford, Neill R. , Silber, Michael H. , Louis, Erik K. St. , St Louis, Erik K, St Louis, E K , Boeve, Brad , McCarter, Stuart J

Mayo Clinic

Sleep | June 11, 2019 | Volume: 42 | Issue: 6 | Pages: No page available

10.1093/sleep/zsz064 | PMID 31184756 Get It

Excessive Daytime Sleepiness in Major Dementia Syndromes
Boeve, Angelica, Ferman, Tanis J. , Aakre, Jeremiah A. , Silber, Michael H. , Fields, Julie A. , Graff‐Radford, Neill R. , Geda, Yonas E. , Graff-Radford, Jonathon, Petersen, Ronald C. , Aakre, Jeremiah, St Louis, Erik, Silber, Michael , Mielke, Michelle, Geda, Yonas, Boeve, Brad , Geda, Yonas E , Ferman, Tanis J , Louis, Erik K. St. , Machulda, Mary M. , Mielke, Michelle M. , Jones, David T. , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

American Journal of Alzheimer's Disease & Other Dementias® | February 11, 2019 | Volume: 34 | Issue: 4 | Pages: 261-264

10.1177/1533317519828046 | PMID 30740984 Get It

There has been no comparison of excessive daytime sleepiness (EDS) in patients with Alzheimer’s disease dementia (AD), dementia with Lewy bodies (DLB), and behavioral variant frontotemporal dementia (bvFTD). We identified patients with mild dementia who met criteria for these disorders who also had the Epworth Sleepiness Scale (ESS) completed. The sample included 17 bvFTD, 111 AD, and 31 DLB. An ESS score ≥10 was considered abnormal and consistent with EDS. Analyses with age and sex as covariates revealed higher mean ESS scores for DLB compared to the other groups (DLB 13.9 [5], bvFTD 9.6 [8], AD 8.8 [5], P < .05). An ESS score ≥10 was significantly more likely to occur in DLB compared to bvFTD or AD (DLB 81% vs bvFTD 47% vs AD 45%, P < .01). In patients with mild dementia, EDS is greatest in DLB and comparably lower in bvFTD and AD.
Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
Ljubenkov, Peter A. , Staffaroni, Adam M. , Allen, Isabel Elaine , Heuer, Hilary W. , Karydas, Anna, Kornak, John , Grinberg, Lea T. , Fagan, Anne M. , Jerome, Gina, Kramer, Joel H. , Miller, Bruce L. , Boxer, Adam L. , Rosen, Howard J. , Boeve, Brad F, Miller, Bruce L , Grinberg, Lea , Rojas, Julio C. , Wang, Ping , Cobigo, Yann , Seeley, William W. , Spina, Salvatore , Knopman, David S. , Boeve, Bradley F. , Dickerson, Bradford Clark

Mayo Clinic

Annals of Clinical and Translational Neurology | September 21, 2018 | Volume: 5 | Issue: 10 | Pages: 1250-1263

10.1002/acn3.643 | PMID 30349860 Get It

AbstractObjectiveThe prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tau181, and amyloid beta1‐42was examined in frontotemporal dementia subtypes.MethodsWe compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotemporal dementia, 24 with semantic variant primary progressive aphasia, and 26 with nonfluent variant primary progressive aphasia. Linear mixed effect models were used to assess the value of baseline biomarkers in predicting clinical and radiographic change in patient cohorts over multiple yearly follow up visits.ResultsNeurofilament light chain concentrations were lowest in controls. Elevated baseline neurofilament light chain predicted faster worsening in clinical severity, frontotemporal volume and frontotemporal fractional anisotropy in patients with behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. High total tau similarly predicted faster progression in nonfluent variant primary progressive aphasia. In behavioral variant frontotemporal dementia, higher phosphorylated tau181predicted faster clinical progression whereas lower amyloid beta1‐42predicted faster volumetric and fractional anisotropy reduction. Neurofilament light chain and phosphorylated tau181were of greater predictive value in patients with tau pathology as compared toTDP‐43 pathology. Baseline neurofilament light chain correlated with baseline clinical severity and frontotemporal volume in behavioral variant frontotemporal dementia. Baseline total tau correlated with baseline clinical severity in semantic variant primary progressive aphasia.InterpretationHigh cerebrospinal fluid neurofilament light chain predicts more aggressive disease in behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. Total tau, phosphorylated tau181, and amyloid beta1‐42also predict some measures of disease aggressiveness in frontotemporal dementia.